The US Supreme Court’s decision on June 25 has fundamentally reshaped Bayer’s legal landscape, handing the German conglomerate its biggest courtroom win in years. The stock reacted explosively, surging by as much as 20% on Thursday — the sharpest single-day gain since 2003 — and pushing the seven-day advance to roughly 23%. By Friday’s close, shares stood at €46.61, still about 7% below the 52-week high of €49.93. Goldman Sachs promptly raised its price target to €55, arguing the ruling effectively ends a decade of litigation overhang tied to glyphosate.
At the heart of the decision is the case Durnell v. Monsanto, a Bayer subsidiary. In a 7-2 vote, the Supreme Court ruled that federal approvals from the Environmental Protection Agency (EPA) preempt state-level lawsuits alleging inadequate warning labels. The majority leaned on the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) to establish that once the EPA deems a product safe, individual states cannot impose additional labeling requirements through litigation. Bayer hailed the verdict as a win for scientific clarity and regulatory consistency, and expects that current and future Roundup-related claims can now be dismissed.
But the glyphosate saga is not entirely closed. The next critical milestone comes on July 9 in Missouri, where a court will hold a final hearing on a proposed $7.25 billion settlement. Media reports have hinted at possible delays, but if the judge grants final approval, a major chunk of uncertainty will evaporate, paving the way for sharply lower legal outflows. Bayer’s finance chief Wolfgang Nickl has already flagged that the company expects roughly €5 billion in legal costs for the full year 2026, after a first-quarter free cash flow drain of €2.32 billion — much of it linked to ongoing Roundup and PCB disputes.
Should investors sell immediately? Or is it worth buying Bayer?
The balance sheet remains strained despite the legal victory. Bayer carries heavy debt, negative free cash flow, and a pharmaceutical pipeline hampered by looming patent expirations on key drugs. The Supreme Court ruling does little to address those operational pressures, meaning the fundamental turnaround story hinges on more than just courtroom success.
Technically, the stock is flashing warning signals after the blistering rally. The Relative Strength Index has shot up to around 80, a deeply overbought reading that historically precedes pullbacks. With annualized volatility near 58%, sharp reversals are a real risk. Still, the price holds comfortably above its 200-day moving average, and the long-term trend remains intact. The July 9 hearing will be the next genuine catalyst: a green light for the settlement could open the door to further upside, while any hiccup might trigger profit-taking after the recent euphoria.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 27 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 27.
Bayer: Buy or sell? Read more here...
